SUPRIYA Supriya Lifescience Q4 FY26 results (Jan–Mar 2026) and concall
Supriya Lifescience delivered strong Q4 and FY26 results, achieving its revenue and exceeding its EBITDA margin guidance. The company successfully navigated a USFDA surprise inspection for its Lote facility, receiving a VAI classification. Despite Q4 headwinds, new product launches contributed positively, and the company is focused on strategic capacity expansion and R&D for future growth, though working capital days have increased.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 50.5%, net profit up 48.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 +20% | 206 +11% | 277 +51% |
| EBITDA | 65 | 66 | 68 | 52 | 73 +12% | 72 +9% | 98 +44% |
| Net profit | 46 | 47 | 50 | 35 | 50 +9% | 50 +6% | 74 +48% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
